ST Chang Medicine: revenue and other indicators falsified, company's stock may be delisted.

ST Changyao announced that the company's stock may be delisted. On January 21, 2026, its stock price was 0.64 yuan/share, continuously below 1 yuan for 15 consecutive trading days, with a market value of 2.24 billion yuan, and continuously below 3 billion yuan for 9 days. In 2021, 2022, and 2023, the company inflated its revenue by 215.32 million yuan, 283.73 million yuan, and 233.63 million yuan respectively. It is expected that the net assets at the end of 2025 will be negative. In addition, Changjiang Xing and 7 other subsidiaries have changed their bankruptcy administrators, and Yiheng Technology is expected to be shut down for a long time. The company also faces risks such as litigation, debt default, account freeze, and tax arrears of subsidiaries.